Lineage Cell Therapeutics, INC

Lineage Cell Therapeutics reports annual meeting voting results and the withdrawal of a CIRM grant application for OPC1.

Lineage Cell Therapeutics reported Q1 2026 financial results, highlighting positive Phase 1/2a data for OpRegen, the launch of a new corneal cell therapy program (COR1), and advancements in manufacturing technology.

Lineage Cell Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting significant clinical and manufacturing advancements alongside increased net losses driven by non-cash expenses.

Lineage Cell Therapeutics, Inc. withdrew its CIRM grant application for OPC1 spinal cord injury treatment but plans to resubmit in January 2026 without impacting current development.

Lineage Cell Therapeutics, Inc. announced the achievement of a key development milestone for its OpRegen program, triggering a $5 million payment from Genentech and Roche.

Lineage Cell Therapeutics, Inc. announced the sale of 12 million common shares to Janus Henderson Investors for $21 million in gross proceeds.

Lineage Cell Therapeutics reported a significant net loss in Q3 2025, driven by non-cash charges, while advancing its OpRegen and OPC1 clinical programs and securing a new collaboration for ReSonance.

Lineage Cell Therapeutics reported a significant net loss for Q2 2025, primarily driven by a $14.8 million intangible asset impairment related to the abandoned VAC platform, despite positive clinical updates for OpRegen and OPC1.

Lineage Cell Therapeutics announces its financial results for the first quarter of 2025, showcasing advancements in its allogeneic cell therapy programs for neurological and ophthalmic conditions.

Lineage Cell Therapeutics reported its financial results for the third quarter of 2024, highlighting progress in its cell therapy programs and ongoing collaborations.

Lineage Cell Therapeutics reported a net loss of $12.3 million for the first half of 2024, with a decrease in collaboration revenue offset by reduced research and development expenses.

Lineage Cell Therapeutics reported a net loss of $6.5 million for the first quarter of 2024, with a decrease in collaboration revenue offset by a recent capital raise.

Lineage Cell Therapeutics, Inc. reported significant progress in its cell therapy pipeline and collaborations for 2025, alongside a substantial increase in net operating losses.

Lineage Cell Therapeutics details its 2024 financial results and provides updates on its key programs, including OpRegen for geographic atrophy and OPC1 for spinal cord injuries.

Lineage Cell Therapeutics has entered into a separation, release, and consulting agreement with Dr. Gary S. Hogge, effective November 30, 2023, which includes separation benefits and a consulting period.

Neal C. Bradsher, a Director and 10% Owner of Lineage Cell Therapeutics, Inc., reported transactions involving stock options.

Anula Jayasuriya, a Director at Lineage Cell Therapeutics, Inc., acquired 125,000 stock options.

Michael H. Mulroy, a Director at Lineage Cell Therapeutics, Inc., acquired 125,000 stock options with an exercise price of $1.30, vesting on July 1, 2027.

Lineage Cell Therapeutics' President and CEO, Brian M. Culley, has filed a Form 4 indicating a planned purchase of 15,000 common shares.

Lineage Cell Therapeutics' President and CEO, Brian M. Culley, was granted 3.25 million employee stock options with an exercise price of $1.84.

Lineage Cell Therapeutics' Chief Financial Officer, Jill Ann Howe, was granted 1,050,000 employee stock options with an exercise price of $1.84.

Lineage Cell Therapeutics, Inc. has updated its 2025 Annual Meeting proxy statement to reflect the appointment of Baker Tilly US, LLP as its new independent registered public accounting firm, succeeding Moss Adams LLP due to a merger.

Lineage Cell Therapeutics will hold its annual shareholder meeting on June 26, 2025, to vote on director elections, auditor ratification, executive compensation, and an equity incentive plan amendment.

Lineage Cell Therapeutics is holding its 2025 annual meeting to elect directors, ratify the auditor, approve executive compensation, and amend the equity incentive plan.

Lineage Cell Therapeutics is holding a special shareholder meeting to approve the issuance of common shares and warrants to Broadwood Partners, aiming to raise approximately $6 million.

Lineage Cell Therapeutics will hold its annual shareholder meeting on June 11, 2024, to elect directors, ratify the appointment of its accounting firm, and approve executive compensation.

Lineage Cell Therapeutics is holding its annual shareholder meeting on June 11, 2024, to vote on the election of directors, ratification of auditors, and executive compensation.

Broadwood Partners and affiliates reported a decrease in their beneficial ownership of Lineage Cell Therapeutics common shares to 23.1% following the issuer's recent share sale.

Broadwood Partners, Broadwood Capital, and Neal C. Bradsher have increased their beneficial ownership in Lineage Cell Therapeutics, Inc. to 24.5% following a shareholder vote approving a significant transaction.

Jorey Chernett has reported beneficial ownership of 5.01% of Lineage Cell Therapeutics, Inc.'s common stock, totaling 11,445,003 shares.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 1.0% beneficial ownership stake in Lineage Cell Therapeutics Inc., totaling 2,234,545 common shares.

BlackRock, Inc. has filed a Schedule 13G, revealing a 5.0% beneficial ownership stake in Lineage Cell Therapeutics Inc., totaling 11,453,305 common shares.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.6% beneficial ownership stake in Lineage Cell Therapeutics Inc. as of December 31, 2024.